SCHEMBL29922833

SCHEMBL29922833

CCOc1cccc(C=O)c1OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ LMNA P02545 1/20 0.47
▸ SRC P12931 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ GSK3A P49840 1/20 0.45
▸ TLR2 O60603 1/20 0.44
▸ ERN1 O75460 1/20 0.44
▸ TLR1 Q15399 1/20 0.44
▸ TLR6 Q9Y2C9 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ PTGDR2 Q9Y5Y4 1/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181586 1.00 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL7494720 0.90 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL1125257 0.89 SRC (0.58) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL1253039 0.89 CA1 (0.54) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL28228828 0.88 LMNA (0.47) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL16161550 0.87 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL30485561 0.87 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL7360395 0.87 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HPGDHTTLMNA
SCHEMBL9248575 0.86 PTGDR2 (0.60) ALDH1A1SMN1; SMN2HPGDHTTSRC
SCHEMBL30598769 0.86 L3MBTL1 (0.51) ALDH1A1SMN1; SMN2HPGDHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591305-B2 Method for producing fisetin or fisetin derivatives DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2023-02-28 — — US disclosed
US-20220220088-A1 METHOD FOR PRODUCING FISETIN OR FISETIN DERIVATIVES DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2022-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220088-A1 METHOD FOR PRODUCING FISETIN OR FISETIN DERIVATIVES FIS1, DNM2, SIRT5 ALDH1A1 1774/4885SMN1; SMN2 4275/4885HPGD 197/4885
US-11591305-B2 Method for producing fisetin or fisetin derivatives FIS1, DNM2, SIRT5 ALDH1A1 1774/4885SMN1; SMN2 4275/4885HPGD 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback